Biopharm Asia Announces Approval of 15c2-11 Filing and Anticipates OTCBB Listing

(firmenpresse) - TONGHUA, CHINA -- (Marketwire) -- 12/18/12 -- Biopharm Asia, Inc. (PINKSHEETS: BFAR) is pleased to announce that Biopharm Asia, Inc. received approval for the recently submitted 15c2-11 filing late on Friday Dec 14th.

The Company will now seek listing with the OTC Bulletin Board at the earliest possible opportunity.

This is a significant step in the growth and development of Biopharm Asia, Inc. The approval and the subsequent OTC listing will allow the company to access additional capital market and investors through new merger and acquisition targets. Biopharm Asia is excited to continue its commitment to increasing transparency, exposure and providing liquidity for its shareholders.

The information in this release includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These forward-looking statements, specifically statements relating to listing and trading on the OTCBB, contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Biopharm Asia to be materially different from the statements made herein. Although the Company believes that its expectations are based on reasonable assumptions, actual results may differ materially.



Contact:
Biopharm Asia, Inc
Investor Relations
(86)130-2919-4689

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 18.12.2012 - 14:00 Uhr
Sprache: Deutsch
News-ID 213826
Anzahl Zeichen: 0

contact information:
Town:

TONGHUA, CHINA

Kategorie:

Commercial & Investment Banking

Diese Pressemitteilung wurde bisher 224 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Biopharm Asia Announces Approval of 15c2-11 Filing and Anticipates OTCBB Listing"
steht unter der journalistisch-redaktionellen Verantwortung von

Biopharm Asia, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Biopharm Asia Intends to Reinstate Listing on OTCBB ...

TONGHUA, CHINA -- (Marketwire) -- 11/19/12 -- Biopharm Asia, Inc. (PINKSHEETS: BFAR) is pleased to announce that Biopharm Asia, Inc. has finished the audit of the previous two fiscal years' financial statements. The Company has prepared a 15c 2 ...

BioPharm Asia Acquires Specialty Hospital in Fujian ...

NEW YORK, NY and TONGHUA, CHINA -- (Marketwire) -- 01/26/12 -- BioPharm Asia, Inc. (PINKSHEETS: BFAR) (the "Company") announced today that the company entered into an agreement to acquire Xiamen Tongji Hospital, a privately owned gynecolo ...

BioPharm Asia Announces Hospital Management Contract ...

NEW YORK, NY and TONGHUA, CHINA -- (Marketwire) -- 12/19/11 -- BioPharm Asia (PINKSHEETS: BFAR) and Elite Capital Group announced today the signing of a consulting agreement for the development of a 1,000-bed Fangzhuang Hospital and Training Center ...

Alle Meldungen von Biopharm Asia, Inc.